This activation stimulates the secretion of anti-tumor cytokines such as IL-8, MCP-1, and IFN-alpha, and triggers the release of TRAIL (TNF-related apoptosis-inducing ligand), enhancing the anti-tumor effect. Here, CCL2 is linked to neoplasm.